istock-183060916

oonal / iStockphoto.com

19 February 2018Americas

Roche to make $1.9bn acquisition

Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

Roche to pay $2.4bn for remainder of Foundation Medicine

20 June 2018 Switzerland-based Roche has agreed to pay $2.4 billion to acquire the remainder of Foundation Medicine, a molecular and genomic analysis company headquartered in Cambridge, Massachusetts.

Roche to make $4.3bn gene therapy acquisition

25 February 2019 Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

Roche to pay $2.4bn for remainder of Foundation Medicine

20 June 2018 Switzerland-based Roche has agreed to pay $2.4 billion to acquire the remainder of Foundation Medicine, a molecular and genomic analysis company headquartered in Cambridge, Massachusetts.

Roche to make $4.3bn gene therapy acquisition

25 February 2019 Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

Roche to pay $2.4bn for remainder of Foundation Medicine

20 June 2018 Switzerland-based Roche has agreed to pay $2.4 billion to acquire the remainder of Foundation Medicine, a molecular and genomic analysis company headquartered in Cambridge, Massachusetts.

Roche to make $4.3bn gene therapy acquisition

25 February 2019 Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent